Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.71 |
| ▸ | MEN1 | O00255 | 3/20 | 0.71 |
| ▸ | F13A1 | P00488 | 3/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | GLA | P06280 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.45 |
| ▸ | LTB4R | Q15722 | 5/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | OXER1 | Q8TDS5 | 1/20 | 0.40 |
| ▸ | MC4R | P32245 | 1/20 | 0.40 |
| ▸ | MC5R | P33032 | 1/20 | 0.40 |
| ▸ | MC3R | P41968 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9334268 | 0.94 | KMT2A (0.80) | KMT2AMEN1F13A1CYP1A2CYP2D6 | |
| SCHEMBL31672143 | 0.88 | KMT2A (0.91) | KMT2AMEN1F13A1CYP1A2CYP2D6 | |
| SCHEMBL9297012 | 0.88 | KMT2A (0.91) | KMT2AMEN1F13A1CYP1A2CYP2D6 | |
| SCHEMBL498806 | 0.88 | KMT2A (0.91) | KMT2AMEN1F13A1CYP1A2CYP2D6 | |
| SCHEMBL31311344 | 0.88 | KMT2A (0.91) | KMT2AMEN1F13A1CYP1A2CYP2D6 | |
| SCHEMBL8644297 | 0.88 | KMT2A (0.91) | KMT2AMEN1F13A1CYP1A2CYP2D6 | |
| SCHEMBL591281 | 0.88 | KMT2A (0.91) | KMT2AMEN1F13A1CYP1A2CYP2D6 | |
| SCHEMBL591648 | 0.88 | KMT2A (0.91) | KMT2AMEN1F13A1CYP1A2CYP2D6 | |
| SCHEMBL4634469 | 0.88 | KMT2A (0.91) | KMT2AMEN1F13A1CYP1A2CYP2D6 | |
| SCHEMBL18696077 | 0.87 | KMT2A (0.59) | KMT2AMEN1F13A1CYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9045421-B2 | Reagent and method for detection of carboxylic acids by mass spectrometry | UNIVERSITY OF WASHINGTON (US) | 2015-06-02 | — | — | US | disclosed |
| US-20150079607-A1 | METHODS FOR MONITORING NEUROINFLAMMATORY DESTRUCTION OF NEURONS AND FOR TREATING DISEASES HAVING AN INFLAMMATORY COMPONENT RELATED TO PHOSPHOLIPASE A2 | Philadelphia Health And Education Corporation, d/b/a Drexel University College of Medicine (US) | 2015-03-19 | — | — | US | disclosed |
| US-8785401-B2 | Methods for treating diseases having an inflammatory component related to phospholipase A2 | PHILADELPHIA HEALTH & EDUCATION CORPORATION (US) | 2014-07-22 | — | — | US | disclosed |
| US-8106019-B2 | Heptapeptide having the sequence of CHEASQC; Multiple Sclerosis, Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis | PHILADELPHIA HEALTH & EDUCATION CORPORATION (US) | 2012-01-31 | — | — | US | disclosed |
| US-20110294153-A1 | REAGENT AND METHOD FOR DETECTION OF CARBOXYLIC ACIDS BY MASS SPECTROMETRY | WASHINGTON, UNIVERSITY OF (US) | 2011-12-01 | — | — | US | disclosed |
| US-20090181879-A1 | Methods for Monitoring Neuroinflammatory Destruction of Neurons and for Treating Diseases Having an Inflammatory component related to phospholipase A2 | PHILADELPHIA HEALTH & EDUCATION CORPORATION D/B/A DREXEL UNIVERSITY COLLEGE OF MEDICINE (US) | 2009-07-16 | — | — | US | disclosed |
| EP-1915613-A4 | METHODS FOR MONITORING NEUROINFLAMMATORY DESTRUCTION OF NEURONS AND FOR TREATING DISEASES HAVING AN INFLAMMATORY COMPONENT RELATED TO PHOSPHOLIPASE A2 | PHILADELPHIA HEALTH & EDUCATIO (US) | 2008-11-05 | — | — | EP | disclosed |
| US-20080249027-A1 | CHEC-7 a novel sPLA2 inhibitor and methods of use for treating neurological and inflammatory disorders | DREXEL UNIVERSITY | 2008-10-09 | — | — | US | disclosed |
| EP-1915613-A2 | METHODS FOR MONITORING NEUROINFLAMMATORY DESTRUCTION OF NEURONS AND FOR TREATING DISEASES HAVING AN INFLAMMATORY COMPONENT RELATED TO PHOSPHOLIPASE A2 | Philadelphia Health and Education Corporation (US) | 2008-04-30 | — | — | EP | disclosed |
| US-7364787-B2 | Sphingolipid ceramide N-deacylase, methods for producing sphingolipids and sphingolipid derivatives, and sphingolipid ceramide N-deacylase gene | TAKARA BIO, INC. (JP) | 2008-04-29 | — | — | US | disclosed |
| US-6821761-B2 | CEREBROSIDES/GANGLIOSIDES; DERIVED FROM PSEUDOMONAS OR SHEWANELLA | TAKARA BIO, INC. (JP) | 2004-11-23 | — | — | US | disclosed |
| US-20030166250-A1 | Sphingolpid ceramide N-deacylase, methods for producing sphingolipids and sphingolipid derivatives, and sphingolipid ceramide N-deacylase gene | TAKARA SHUZO CO., LTD. | 2003-09-04 | — | — | US | disclosed |
| EP-1135141-A4 | PHOSPHOLIPASE INHIBITORS FOR THE TREATMENT OF CANCER | ANALYTICA LTD (AU) | 2003-03-05 | — | — | EP | disclosed |
| US-6428999-B1 | USEFUL IN MEDICINE, CARBOHYDRATE ENGINEERING, CELL ENGINEERING | TAKARA SHUZO CO., LTD. (JP) | 2002-08-06 | — | — | US | disclosed |
| US-20020086410-A1 | SPHINGOLIPID CERAMIDE N-DEACYLASE, METHODS FOR PRODUCING SPHINGOLIPIDS AND SPHINGOLIPID DERIVATIVES, AND SPHINGOLIPID CERAMIDE N-DEACYLASE GENE | TAKARA SHUZO CO., LTD. (JP) | 2002-07-04 | — | — | US | disclosed |
| EP-1135141-A1 | PHOSPHOLIPASE INHIBITORS FOR THE TREATMENT OF CANCER | Analytica Ltd. (AU) | 2001-09-26 | — | — | EP | disclosed |
| WO-2000028997-A1 | PHOSPHOLIPASE INHIBITORS FOR THE TREATMENT OF CANCER | ANALYTICA LTD (AU) | 2000-05-25 | — | — | WO | disclosed |
| WO-1999029726-A1 | PHOSPHOLIPASE INHIBITOR | HSC (PLA) PTY. LTD. (AU) | 1999-06-17 | — | — | WO | disclosed |
| EP-0707063-B1 | Glycolipid ceramide deacylase | TAKARA SHUZO CO (JP) | 1998-06-17 | — | — | EP | disclosed |
| EP-0707063-A1 | Glycolipid ceramide deacylase | TAKARA SHUZO CO. LTD. (JP) | 1996-04-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110294153-A1 | REAGENT AND METHOD FOR DETECTION OF CARBOXYLIC ACIDS BY MASS SPECTROMETRY | NAAA, CA1, CA12 | KMT2A 1332/4885MEN1 3450/4885F13A1 134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.